/ / /
Nathan joined Gurnet Point Capital in 2022 and currently is a Senior Analyst on the investment team. He is involved in all aspects of the investment process, from sourcing to transaction execution and most recently led clinical diligence on the Radius Health buyout.
Prior to joining Gurnet Point, Nathan was a Senior Analyst at ClearView Healthcare Partners, where he advised clients from leading VC-backed biotechs to Fortune 500 pharmaceuticals on asset, franchise, and corporate-level strategy. Previous work included clinical trial design, commercial assessments, and post-merger integration across a wide spectrum of therapeutic areas. Nathan also has several years of clinical and translational research experience in cardiac transplantation and metabolic disorders.
Nathan graduated from Columbia University where he received his B.A. in Neurobiology and completed extensive coursework in the Biotechnology M.A. program.